{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:27:26Z","timestamp":1722385646289},"reference-count":148,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.mcna.2024.03.011","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T02:05:28Z","timestamp":1718244328000},"page":"843-869","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Therapies in Outpatient Pulmonary Medicine"],"prefix":"10.1016","volume":"108","author":[{"given":"Laura","family":"Granados","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey D.","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0025-7125(02)00087-1","article-title":"Pathogenesis of asthma","volume":"86","author":"Jarjour","year":"2002","journal-title":"Med Clin North Am"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1183\/09031936.00138707","article-title":"Global strategy for asthma management and prevention: GINA executive summary","volume":"31","author":"Bateman","year":"2008","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib3","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 Focused updates to the asthma management guidelines: a report from the national asthma education and prevention program coordinating committee expert panel working group","volume":"146","author":"Cloutier","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.mcna.2022.08.003","article-title":"Advances in evaluation and treatment of severe asthma (Part One)","volume":"106","author":"Fanta","year":"2022","journal-title":"Med Clin North Am"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.011_bib6","unstructured":"Global initiative for asthma, Global strategy for asthma management and prevention, Published online July 2023. Available at: www.ginasthma.org, (Accessed January 1, 2023), 2023."},{"issue":"7","key":"10.1016\/j.mcna.2024.03.011_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(23)00230-8","article-title":"2023 GINA report for asthma","volume":"11","author":"Venkatesan","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib8","doi-asserted-by":"crossref","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib9","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jaip.2019.03.008","article-title":"Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent","volume":"7","author":"Krings","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.mcna.2022.08.004","article-title":"Advances in evaluation and treatment of severe asthma (Part Two)","volume":"106","author":"Fanta","year":"2022","journal-title":"Med Clin North Am"},{"issue":"10","key":"10.1016\/j.mcna.2024.03.011_bib12","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mcna.2024.03.011_bib13","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib15","doi-asserted-by":"crossref","first-page":"1902420","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Erin","year":"2020","journal-title":"Eur Respir J"},{"issue":"13","key":"10.1016\/j.mcna.2024.03.011_bib16","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib17","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib18","first-page":"540","article-title":"Safety of reslizumab in uncontrolled asthma with eosinophilia: a pooled analysis from 6 trials","volume":"8","author":"Christian Virchow","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.mcna.2024.03.011_bib19","doi-asserted-by":"crossref","unstructured":"Fanta, \u201cAdvances in Evaluation and Treatment of Severe Asthma (Part Two)\u201d; Brusselle and Koppelman, \u201cBiologic Therapies for Severe Asthma. Medical Clinics 106, no.6 2022: 987-999.","DOI":"10.1016\/j.mcna.2022.08.004"},{"issue":"10013","key":"10.1016\/j.mcna.2024.03.011_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Claus","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.011_bib22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cea.13614","article-title":"Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life french multi-centre adult cohort","volume":"50","author":"Dupin","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.011_bib23","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1016\/j.jaip.2021.02.042","article-title":"Complications of switching from anti-il-5 or anti-il-5r to dupilumab in corticosteroid-dependent severe asthma","volume":"9","author":"Eger","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"26","key":"10.1016\/j.mcna.2024.03.011_bib24","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.011_bib25","unstructured":"Eger et\u00a0al., \u201cComplications of Switching from Anti-IL-5 or Anti-IL-5R to Dupilumab in Corticosteroid-Dependent Severe Asthma.\u201d."},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib26","doi-asserted-by":"crossref","first-page":"2000260","DOI":"10.1183\/13993003.00260-2020","article-title":"Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics","volume":"56","author":"Porsbjerg","year":"2020","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.011_bib27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","article-title":"Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma","volume":"24","author":"Gauvreau","year":"2020","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib28","doi-asserted-by":"crossref","first-page":"2101296","DOI":"10.1183\/13993003.01296-2021","article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","volume":"59","author":"Sverrild","year":"2022","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.mcna.2024.03.011_bib29","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.011_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S2213-2600(18)30367-9","article-title":"Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial","volume":"7","author":"Sadushi-Kolici","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib31","doi-asserted-by":"crossref","first-page":"2101499","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.011_bib32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1164\/rccm.202301-0106PP","article-title":"Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary","volume":"207","author":"Agust\u00ed","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.011_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s41030-023-00233-z","article-title":"The 2023 GOLD report: updated guidelines for inhaled pharmacological therapy in patients with stable COPD","volume":"9","author":"Terry","year":"2023","journal-title":"Pulm Ther"},{"issue":"9691","key":"10.1016\/j.mcna.2024.03.011_bib34","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"issue":"9691","key":"10.1016\/j.mcna.2024.03.011_bib35","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE Trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.011_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.011_bib38","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1164\/rccm.201309-1634ST","article-title":"An official American thoracic society\/european respiratory society statement: key concepts and advances in pulmonary rehabilitation","volume":"188","author":"Spruit","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/15412555.2021.2020234","article-title":"Effects of home-based pulmonary rehabilitation on dyspnea, exercise capacity, quality of life and impact of the disease in COPD patients: a systematic review","volume":"19","author":"Mendes Xavier","year":"2022","journal-title":"COPD"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s12913-022-07779-9","article-title":"Effectiveness of home-based pulmonary rehabilitation programs for patients with chronic obstructive pulmonary disease (COPD): systematic review","volume":"22","author":"Stafinski","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"21","key":"10.1016\/j.mcna.2024.03.011_bib41","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa030287","article-title":"A\u00a0randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema","volume":"348","author":"Fishman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.mcna.2024.03.011_bib42","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJM199604253341704","article-title":"Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema","volume":"334","author":"Sciurba","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mcna.2024.03.011_bib43","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1164\/rccm.201707-1327OC","article-title":"A\u00a0multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM)","volume":"196","author":"Kemp","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.mcna.2024.03.011_bib44","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1164\/rccm.201902-0383OC","article-title":"Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). a multicenter, open-label randomized controlled clinical trial","volume":"200","author":"Criner","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib45","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official american thoracic society\/european respiratory society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.mcna.2024.03.011_bib46","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.mcna.2024.03.011_bib47","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12890-019-1030-4","article-title":"Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis","volume":"20","author":"Richeldi","year":"2020","journal-title":"BMC Pulm Med"},{"year":"2022","series-title":"Nintedanib capsules package insert","key":"10.1016\/j.mcna.2024.03.011_bib49"},{"issue":"22","key":"10.1016\/j.mcna.2024.03.011_bib50","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A\u00a0phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N\u00a0Engl J Med"},{"year":"2014","series-title":"Pirfenidone capsules [package insert]","key":"10.1016\/j.mcna.2024.03.011_bib51"},{"issue":"9779","key":"10.1016\/j.mcna.2024.03.011_bib52","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.mcna.2024.03.011_bib53","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study","volume":"9","author":"Nathan","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib54","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.011_bib55","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1007\/s12325-022-02229-8","article-title":"The antifibrotic effects of inhaled treprostinil: an emerging option for ILD","volume":"39","author":"Kolb","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib56","article-title":"Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis","volume":"9","author":"Nathan","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib57","doi-asserted-by":"crossref","first-page":"e12063","DOI":"10.1002\/pul2.12063","article-title":"BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPITM in patients with pulmonary arterial hypertension","volume":"12","author":"Spikes","year":"2022","journal-title":"Pulm Circ"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib58","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02414-2022","article-title":"Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study","volume":"61","author":"Waxman","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.mcna.2024.03.011_bib59","unstructured":"Treprostinil inhalation solution package insert. Research Triangle Park NC: United Therapeutics Corp; 2023."},{"key":"10.1016\/j.mcna.2024.03.011_bib60","unstructured":"Treprostinil Inhalation Powder Package Insert. Research Triangle Park NC: United Therapeutics Corp; 2023.; 2023."},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib61","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00145608","article-title":"Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review","volume":"34","author":"Kovacs","year":"2009","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib62","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.00008611","article-title":"Pulmonary vascular resistances during exercise in normal subjects: a systematic review","volume":"39","author":"Kovacs","year":"2012","journal-title":"Eur Respir J"},{"issue":"13","key":"10.1016\/j.mcna.2024.03.011_bib63","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/CIRCULATIONAHA.115.020207","article-title":"Association of Borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program","volume":"133","author":"Maron","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib64","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1164\/rccm.201706-1215OC","article-title":"Mild elevation of pulmonary arterial pressure as a predictor of mortality","volume":"197","author":"Douschan","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.mcna.2024.03.011_bib65","doi-asserted-by":"crossref","first-page":"e009729","DOI":"10.1161\/JAHA.118.009729","article-title":"Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis","volume":"7","author":"Kolte","year":"2018","journal-title":"JAHA"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib66","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib67","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib68","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib69","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1378\/chest.11-0676","article-title":"The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension","volume":"141","author":"Benza","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib70","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1378\/chest.12-0993","article-title":"Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension","volume":"143","author":"Chan","year":"2013","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/eurheartj\/ehv337","article-title":"Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial","volume":"37","author":"Ehlken","year":"2016","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.mcna.2024.03.011_bib72","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/eurheartj\/ehaa696","article-title":"Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial","volume":"42","author":"Gr\u00fcnig","year":"2021","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.mcna.2024.03.011_bib73","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.106.618397","article-title":"Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension","volume":"114","author":"Mereles","year":"2006","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib74","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/jcsm.12764","article-title":"Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study","volume":"12","author":"Kramer","year":"2021","journal-title":"J\u00a0cachexia sarcopenia muscle"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.011_bib75","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1086\/682217","article-title":"Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency","volume":"5","author":"Ruiter","year":"2015","journal-title":"Pulm Circ"},{"issue":"23","key":"10.1016\/j.mcna.2024.03.011_bib76","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib77","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.mcna.2024.03.011_bib78","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.mcna.2024.03.011_bib79","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Lewis","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib80","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2125.2005.02383.x","article-title":"Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension","volume":"60","author":"Gideon","year":"2005","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.011_bib81","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/00912709922008380","article-title":"Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin","volume":"39","author":"Weber","year":"1999","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib82","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","article-title":"Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects","volume":"48","author":"Wrishko","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.011_bib83","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.011_bib84","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study","volume":"43","author":"Sastry","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.mcna.2024.03.011_bib85","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib86","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/13543784.2011.565048","article-title":"Riociguat for the treatment of pulmonary hypertension","volume":"20","author":"Schermuly","year":"2011","journal-title":"Expet Opin Invest Drugs"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib87","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib88","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A\u00a0comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib89","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.011_bib90","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.510300307","article-title":"Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension","volume":"30","author":"Krowka","year":"1999","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib91","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib92","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib93","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.chest.2015.11.005","article-title":"Treprostinil administered to treat pulmonary arterial hypertension using a fully implantable programmable intravascular delivery system","volume":"150","author":"Bourge","year":"2016","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.mcna.2024.03.011_bib94","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.healun.2018.06.006","article-title":"Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension","volume":"37","author":"Richter","year":"2018","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"18","key":"10.1016\/j.mcna.2024.03.011_bib95","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib96","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1164\/rccm.202107-1766OC","article-title":"Efficacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the INCREASE trial","volume":"205","author":"Nathan","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib97","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Zhi-Cheng","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib98","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. a double-blind placebo-controlled clinical trial","volume":"201","author":"James White","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"26","key":"10.1016\/j.mcna.2024.03.011_bib99","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib100","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"G\u00e9rald","year":"2012","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.mcna.2024.03.011_bib101","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40261-019-00841-1","article-title":"Effect of combination therapy of endothelin receptor antagonist and phosphodiesterase-5 inhibitor on clinical outcome and pulmonary haemodynamics in patients with pulmonary arterial hypertension: a meta-analysis","volume":"39","author":"Kirtania","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib102","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/rccm.202004-1006OC","article-title":"Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension","volume":"203","author":"Badagliacca","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib103","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1183\/09031936.00116313","article-title":"Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study","volume":"43","author":"Sitbon","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib104","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.chest.2019.09.009","article-title":"Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension","volume":"157","author":"D\u2019Alto","year":"2020","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib105","doi-asserted-by":"crossref","first-page":"1901030","DOI":"10.1183\/13993003.01030-2019","article-title":"Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial","volume":"54","author":"Torres","year":"2019","journal-title":"Eur Respir J"},{"issue":"16","key":"10.1016\/j.mcna.2024.03.011_bib106","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mcna.2024.03.011_bib107","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2013.05.075","article-title":"Pulmonary artery denervation to treat pulmonary arterial hypertension","volume":"62","author":"Chen","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.011_bib108","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jcin.2019.12.027","article-title":"Intravascular ultrasound pulmonary artery denervation to treat pulmonary arterial hypertension (TROPHY1)","volume":"13","author":"Rothman","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib109","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000107791","article-title":"Clinical and Hemodynamic Effects of Bosentan Dose Optimization in Symptomatic Heart Failure Patients with Severe Systolic Dysfunction, Associated with Secondary Pulmonary Hypertension - A Multi-Center Randomized Study","volume":"109","author":"Kaluski","year":"2008","journal-title":"Cardiology"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hlc.2016.09.004","article-title":"Pilot Study of Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension (BADDHY-Trial)","volume":"26","author":"Koller","year":"2017","journal-title":"Heart, Lung and Circulation"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib111","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in Pulmonary Hypertension Due to Left Ventricular Dysfunction","volume":"51","author":"Vachi\u00e9ry","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib112","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ejhf.47","article-title":"Additional Use of a Phosphodiesterase 5 Inhibitor in Patients with Pulmonary Hypertension Secondary to Chronic Systolic Heart Failure: A Meta-analysis","volume":"16","author":"Wu","year":"2014","journal-title":"European Journal of Heart Failure"},{"issue":"14","key":"10.1016\/j.mcna.2024.03.011_bib113","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","article-title":"Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension","volume":"116","author":"Lewis","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib114","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijcard.2011.10.064","article-title":"Therapeutic Potential of Sildenafil in Patients with Heart Failure and Reactive Pulmonary Hypertension","volume":"154","author":"Dumitrescu","year":"2012","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.mcna.2024.03.011_bib115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijcard.2018.12.078","article-title":"Therapeutic Potential of Phosphodiesterase Type 5 Inhibitors in Heart Failure with Preserved Ejection Fraction and Combined Post- and Pre-Capillary Pulmonary Hypertension","volume":"283","author":"Kramer","year":"2019","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib116","article-title":"2022 ESC\/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"European Respiratory"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib117","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/jth.14649","article-title":"A\u00a0multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension","volume":"18","author":"Bunclark","year":"2020","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib118","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.healun.2022.02.002","article-title":"Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension","volume":"41","author":"Humbert","year":"2022","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.011_bib119","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jtcvs.2018.04.110","article-title":"Residual pulmonary hypertension after pulmonary endarterectomy: A meta-analysis","volume":"156","author":"Hsieh","year":"2018","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib120","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.healun.2015.10.030","article-title":"Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension","volume":"35","author":"Wiedenroth","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib121","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1253\/circj.CJ-16-1075","article-title":"Improvement in quality of life and hemodynamics in chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty","volume":"81","author":"Darocha","year":"2017","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib122","doi-asserted-by":"crossref","first-page":"1801915","DOI":"10.1183\/13993003.01915-2018","article-title":"Chronic thromboembolic pulmonary hypertension","volume":"53","author":"Kim","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.011_bib123","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.iccl.2017.09.003","article-title":"Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension","volume":"7","author":"Mahmud","year":"2018","journal-title":"Interventional Cardiology Clinics"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.011_bib124","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mcna.2024.03.011_bib125","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2213-2600(17)30305-3","article-title":"Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study","volume":"5","author":"Ghofrani","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.mcna.2024.03.011_bib126","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J\u00a0Pediatr"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib127","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"issue":"19","key":"10.1016\/j.mcna.2024.03.011_bib128","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10212","key":"10.1016\/j.mcna.2024.03.011_bib129","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.mcna.2024.03.011_bib130","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A\u00a0phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"year":"2023","series-title":"Ivacaftor tablets; ivacaftor tablets), co-packaged for oral use[package insert]","author":"Elexacaftor","key":"10.1016\/j.mcna.2024.03.011_bib131"},{"issue":"15","key":"10.1016\/j.mcna.2024.03.011_bib132","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1042\/CS20170995","article-title":"Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment","volume":"131","author":"Edgeworth","year":"2017","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.011_bib133","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1513\/AnnalsATS.202006-659OC","article-title":"Ivacaftor in people with cystic fibrosis and a 3849+10kb C\u2192T or D1152H residual function mutation","volume":"18","author":"Kerem","year":"2021","journal-title":"Ann Am Thorac Soc"},{"year":"2023","series-title":"Ivacaftor tablets[package insert]","key":"10.1016\/j.mcna.2024.03.011_bib134"},{"issue":"21","key":"10.1016\/j.mcna.2024.03.011_bib135","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.mcna.2024.03.011_bib136","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two phe508del alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.mcna.2024.03.011_bib137","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-ivacaftor in patients with cystic fibrosis and one or two phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib138","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2020.11.003","article-title":"A\u00a0phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor\/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation","volume":"20","author":"McKone","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.011_bib139","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jcf.2020.04.015","article-title":"Tezacaftor\/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations","volume":"19","author":"Munck","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"21","key":"10.1016\/j.mcna.2024.03.011_bib140","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.mcna.2024.03.011_bib141","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N\u00a0Engl J Med"},{"year":"2023","series-title":"Tezacaftor\/ivacaftor [package insert]","key":"10.1016\/j.mcna.2024.03.011_bib142"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.011_bib143","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jcf.2020.11.007","article-title":"Lumacaftor\/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation","volume":"20","author":"Berkers","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib144","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.011_bib145","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.011_bib146","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1513\/AnnalsATS.201609-689OC","article-title":"Lumacaftor\/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR","volume":"14","author":"Rowe","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.011_bib147","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1513\/AnnalsATS.202208-684OC","article-title":"Effects of lumacaftor\/ivacaftor on cystic fibrosis disease progression in children 2 through 5 years of age homozygous for F508del-CFTR: a phase 2 placebo-controlled clinical trial","volume":"20","author":"Stahl","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.011_bib148","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"year":"2023","series-title":"Lumacaftor and ivacaftor tablets[package insert]","key":"10.1016\/j.mcna.2024.03.011_bib149"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524000361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524000361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T06:12:15Z","timestamp":1722319935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712524000361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":148,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0025712524000361"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2024.03.011","relation":{},"ISSN":["0025-7125"],"issn-type":[{"type":"print","value":"0025-7125"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Therapies in Outpatient Pulmonary Medicine","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2024.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}